These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38967473)

  • 21. Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis.
    Chan YH; Lee HF; Chao TF; Wu CT; Chang SH; Yeh YH; See LC; Kuo CT; Chu PH; Wang CL; Lip GYH
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):701-710. PubMed ID: 31745687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adherence to medication and characteristics of Japanese patients with non-valvular atrial fibrillation.
    Suzuki T; Shiga T; Omori H; Tatsumi F; Nishimura K; Hagiwara N
    J Cardiol; 2017 Sep; 70(3):238-243. PubMed ID: 28007412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants.
    Rozjabek HM; Coleman CI; Ashton V; Laliberté F; Oyefesobi P; Lejeune D; Germain G; Schein JR; Yuan Z; Lefebvre P; Peterson ED
    J Med Econ; 2019 Aug; 22(8):751-759. PubMed ID: 30939954
    [No Abstract]   [Full Text] [Related]  

  • 24. Adherence to Oral Anticoagulants in Atrial Fibrillation: An Australian Survey.
    Obamiro KO; Chalmers L; Lee K; Bereznicki BJ; Bereznicki LR
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):337-343. PubMed ID: 29658327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anticoagulation knowledge in patients with atrial fibrillation: An Australian survey.
    Obamiro KO; Chalmers L; Lee K; Bereznicki BJ; Bereznicki LRE
    Int J Clin Pract; 2018 Mar; 72(3):e13072. PubMed ID: 29457323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation.
    Alalwan AA; Voils SA; Hartzema AG
    Am J Health Syst Pharm; 2017 Aug; 74(16):1237-1244. PubMed ID: 28652320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world persistence with direct oral anticoagulants (DOACs) in naïve patients with non-valvular atrial fibrillation.
    Ferroni E; Gennaro N; Costa G; Fedeli U; Denas G; Pengo V; Corti MC
    Int J Cardiol; 2019 Aug; 288():72-75. PubMed ID: 31043323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticoagulant Prescribing for Non-Valvular Atrial Fibrillation in the Veterans Health Administration.
    Rose AJ; Goldberg R; McManus DD; Kapoor A; Wang V; Liu W; Yu H
    J Am Heart Assoc; 2019 Sep; 8(17):e012646. PubMed ID: 31441364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence to Oral Anticoagulant Medications.
    Shani M; Comaneshter D; Lustman A
    Isr Med Assoc J; 2021 Sep; 23(9):580-583. PubMed ID: 34472234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
    Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
    Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between medication adherence and illness perceptions in atrial fibrillation patients treated with direct oral anticoagulants: An observational cross-sectional pilot study.
    Miyazaki M; Nakashima A; Nakamura Y; Sakamoto Y; Matsuo K; Goto M; Uchiyama M; Okamura K; Mitsutake R; Urata H; Kamimura H; Imakyure O
    PLoS One; 2018; 13(9):e0204814. PubMed ID: 30265710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
    Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral anticoagulants usage in Japanese patients aged 18-74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data.
    Ohshima A; Koyama T; Ogawa A; Zamami Y; Tanaka HY; Kitamura Y; Sendo T; Hinotsu S; Miller MW; Kano MR
    Fam Pract; 2019 Nov; 36(6):685-692. PubMed ID: 31329899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Decision Analysis of Percutaneous Left Atrial Appendage Occlusion Relative to Novel and Traditional Oral Anticoagulation for Stroke Prevention in Patients with New-Onset Atrial Fibrillation.
    Micieli A; Wijeysundera HC; Qiu F; Atzema CL; Singh SM
    Med Decis Making; 2016 Apr; 36(3):366-74. PubMed ID: 26139448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.
    McHorney CA; Ashton V; Laliberté F; Germain G; Wynant W; Crivera C; Schein JR; Lefebvre P; Peterson ED
    J Manag Care Spec Pharm; 2017 Sep; 23(9):980-988. PubMed ID: 28854075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developing and Validating a Self-Care Self-Efficacy Scale for Oral Anticoagulation Therapy in Patients With Nonvalvular Atrial Fibrillation: Protocol for a Mixed Methods Study.
    Magon A; Hendriks J; Caruso R
    JMIR Res Protoc; 2024 Sep; 13():e51489. PubMed ID: 39269742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR
    Thompson LE; Maddox TM; Lei L; Grunwald GK; Bradley SM; Peterson PN; Masoudi FA; Turchin A; Song Y; Doros G; Davis MB; Daugherty SL
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trends in Drug Spending of Oral Anticoagulants for Atrial Fibrillation, 2014-2021.
    Lee JS; Han S; Therrien NL; Park C; Luo F; Essien UR
    Am J Prev Med; 2024 Mar; 66(3):463-472. PubMed ID: 37866490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.